This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Alpine Immune Sciences Stock (NASDAQ:ALPN) Get Alpine Immune Sciences alerts:Sign Up Key Stats Today's Range$64.97▼$64.9750-Day Range$64.37▼$64.9752-Week Range$8.33▼$65.00VolumeN/AAverage Volume1.92 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. Read More Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALPN Stock News HeadlinesAlpine Immune Sciences Inc.January 10, 2025 | thestreet.comFrazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture PartnersJanuary 9, 2025 | finance.yahoo.comYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 1 at 1:00 AM | Behind the Markets (Ad)What 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 16, 2024 | markets.businessinsider.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | businesswire.comVertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 7, 2024 | finance.yahoo.comAlpine Immune Sciences IncMay 1, 2024 | morningstar.comMSee More Headlines ALPN Stock Analysis - Frequently Asked Questions How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to analyst estimates of $22.30 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 14.86% and a negative net margin of 65.17%. When did Alpine Immune Sciences IPO? Alpine Immune Sciences (ALPN) raised $77 million in an IPO on Wednesday, June 17th 2015. The company issued 5,500,000 shares at a price of $13.00-$15.00 per share. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Evofem Biosciences (EVFM), Marker Therapeutics (MRKR), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/09/2021Today11/01/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ALPN CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees142Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.18 million Net Margins-65.17% Pretax Margin-64.99% Return on Equity-14.86% Return on Assets-11.82% Debt Debt-to-Equity RatioN/A Current Ratio9.56 Quick Ratio9.56 Sales & Book Value Annual Sales$56.52 million Price / Sales78.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book13.40Miscellaneous Outstanding Shares68,598,000Free Float39,581,000Market Cap$4.46 billion OptionableNo Data Beta0.97 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ALPN) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpine Immune Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPN Stock Alerts